Recent public coverage includes a 2018 article highlighting industry developments and the role of prominent figures in marijuana legalization, reflecting the broader context of the cannabis sector in which WEED, INC. operates.

• Former House Speaker John Boehner is noted as a new face of marijuana legalization, indicating evolving political and social acceptance of cannabis-related businesses [N1].

The company’s extensive proprietary genetic seedbank and ongoing genomic research could position it as a leader in cannabis-derived medical and industrial products. Its strategic real estate assets and planned entry into hemp and infused beverage markets offer potential diversification. The integration of blockchain and digital asset initiatives may provide innovative solutions to banking and supply chain challenges in the cannabis industry. Collaborations with leading scientists and institutions enhance its research credibility. If the company successfully completes its Cannabis Genomic Study and clinical trials, it could develop unique, patentable products and establish a global presence in the emerging cannabis market [S1].

WEED, INC. has not generated revenue and reported significant net losses, with limited liquidity and substantial doubt about its ability to continue as a going concern without additional financing. The Cannabis Genomic Study and clinical trials are capital-intensive and subject to regulatory and scientific risks, including potential failure to complete or achieve desired outcomes. The company’s digital asset projects face regulatory uncertainty and require significant capital. The cannabis industry’s regulatory environment remains complex and evolving, with risks related to legalization and market acceptance. The company’s early-stage status, lack of manufacturing capabilities, and competition from better-financed peers present execution challenges [S1].

WEED, INC.’s moat is primarily based on its proprietary cannabis genetic assets, including a large seedbank with rare Landrace strains, and its ongoing Cannabis Genomic Study which aims to create a global genomic classification of cannabis. The company’s strategic real estate holdings provide tangible asset value and potential operational leverage. Its partnerships with academic institutions and scientific experts, such as the Hebrew University and Professor Elka Touitou, contribute to its intellectual property and research capabilities. However, the company operates in a highly competitive and evolving cannabis industry with many better-financed players, and its early-stage research focus and lack of commercial products limit its current competitive advantage.

• Liquidity and Going Concern Risk: The company has limited cash and liquidity, with a current ratio of 0.04 as of December 31, 2025, and has reported recurring losses. There is substantial doubt about its ability to continue as a going concern without additional financing [S1].
• Regulatory Risk: The cannabis industry is subject to complex and evolving regulations at federal and state levels. Changes or delays in legalization could adversely affect the company’s operations and market opportunities [S1].
• Research and Development Risk: The company’s business depends on successful completion of its Cannabis Genomic Study and clinical trials. Failure to complete or achieve positive results could materially impact its business [S1].
• Market and Competition Risk: The cannabis sector is highly competitive with many better-financed companies. The company’s early-stage status and lack of commercial products limit its competitive position [S1].
• Digital Asset and Technology Risk: The company’s blockchain and digital asset initiatives are in early development and subject to regulatory uncertainty and capital availability, with no assurance of successful launch [S1].

• WEED, INC. is a multi-national bio-pharmaceutical and real estate holding company focused on cannabis-derived compounds for medical and industrial use [S1].
• The company’s short-term focus is on conducting a five-year Cannabis Genomic Study through its wholly-owned subsidiary Sangre AT, LLC, aiming to create a global genomic classification of the Cannabis plant genus [S1].
• Sangre completed a pilot study in 2017-2018 involving 30 cannabis cultivars, with results considered proprietary and foundational for future research [S1].
• WEED Israel Cannabis Ltd., a wholly-owned subsidiary formed in 2018, collaborates with Hebrew University and top scientists to conduct clinical trials and product development, aiming for FDA-quality standards, though U.S. market introduction is restricted by current laws [S1].
• The company had an agreement to acquire patents from Professor Elka Touitou related to cannabinoid bioavailability but terminated it in 2019 due to market downturn and COVID-19 impacts; discussions remain ongoing for future collaboration [S1].
• WEED acquired Hempirical Genetics, LLC in 2022, adding a proprietary seedbank of over 250 cannabis and hemp strains, including rare Landrace varieties, which are carried at cost on the balance sheet [S1].
• The company owns a 44-acre property in Portland, New York, with unlimited water extraction rights, intended for future entry into the hemp and infused beverage markets [S1].
• WEED is exploring integration of blockchain and AI technologies within the regulated cannabis ecosystem and has a strategic partnership with Remergify, Inc. to develop a digital asset ecosystem including WEEDCoin and BUDZCoin, currently in early development [S1].
• The company has limited current revenue (reported as zero for fiscal year 2025) and reported a net loss of approximately $1.37 million for the same period [S1].
• Liquidity ratios as of December 31, 2025, show current assets of $47,705 and current liabilities of $1,248,267, resulting in a current ratio of 0.04, indicating limited short-term liquidity [S1].
• The company has a history of negative cash flows from operations and substantial doubt about its ability to continue as a going concern without additional financing [S1].
• WEED’s long-term plan includes becoming a global seed-to-sale holding company providing infrastructure, financial solutions, product development, and real estate options in the cannabis and hemp markets [S1].
• The company is not currently manufacturing products and does not have third-party manufacturing relationships; manufacturing is planned for later stages after research milestones [S1].
• WEED’s common stock is quoted on the OTCQB market under the ticker BUDZ, with approximately 148 million shares outstanding as of March 30, 2026 [S1].
• The company faces regulatory and market risks inherent in the cannabis industry, including dependence on state-level legalization and evolving federal regulations [S1].
• The company’s research and development efforts, including the Cannabis Genomic Study, depend on securing additional funding and successful completion of clinical trials [S1].
• The company’s digital asset initiatives are subject to regulatory complexity and capital availability, with no assurance of successful launch [S1].
• The company’s real estate holdings provide tangible asset value and potential strategic advantage in the microcap sector [S1].
• The company’s business model and operations have been publicly discussed in news coverage related to marijuana legalization, including a 2018 article highlighting industry developments [N1].